<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054989</url>
  </required_header>
  <id_info>
    <org_study_id>FIRE-01</org_study_id>
    <nct_id>NCT01054989</nct_id>
  </id_info>
  <brief_title>Fat, Inflammation and Insulin Resistance</brief_title>
  <acronym>FIRE</acronym>
  <official_title>Fat, Inflammation and Insulin Resistance (FIRE-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of impaired insulin sensitivity and insulin secretion is thought to be the&#xD;
      basis of type 2 diabetes. Increased free fatty acids levels impair insulin action in muscle&#xD;
      and liver, but also systemic inflammation processes play a role in the development of insulin&#xD;
      resistance.&#xD;
&#xD;
      This study compares the effects of fat and inflammation on insulin sensitivity, systemic&#xD;
      inflammation, energy metabolism, vascular system and neural function in healthy humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dysregulation of lipid metabolism with increased levels of free fatty acids (FFA) is known&#xD;
      represent one key mechanism in the pathophysiology of insulin resistance, which is&#xD;
      subsequently known to be the basis of the development of type 2 diabetes. But also&#xD;
      inflammatory processes, also known as subclinical inflammation, have been shown to be&#xD;
      independently associated with insulin resistance and diabetes development. The aim of this&#xD;
      study is to analyse the causal relationship between FFA and inflammation in the induction of&#xD;
      insulin resistance in healthy humans.&#xD;
&#xD;
      It is known that the parenteral application of lipids over 4-6 hours results in an increase&#xD;
      of FFA and a subsequent induction of a transient insulin resistance in peripheral tissues.&#xD;
      Whether oral fat intake has similar effect is still unknown. On the other hand the oral&#xD;
      intake of a high fat meal acutely increases intestinal permeability and thereby the levels of&#xD;
      bacterial lipopolysaccharide (LPS) in the bloodstream. LPS is known to be a potent stimulator&#xD;
      of immune response on a subclinical level accompanied by elevated levels of immune mediators,&#xD;
      which in turn impair the insulin receptor signalling pathway leading to insulin resistance.&#xD;
      Thus, in this study the effects of fat, both by an oral or parenteral fat load, and by a&#xD;
      short-term LPS-infusion simulating the postprandial systemic LPS peak compared to a control&#xD;
      infusion (glycerol) on insulin resistance is analysed. Insulin resistance and hepatic glucose&#xD;
      production is determined by an hyperinsulinemic euglycemic clamp including glucose tracers.&#xD;
      To detect the effects on the immune system on different levels, we measure 1) circulating&#xD;
      levels of immune mediators by ELISA and bead-based mulitiplex assays, 2) gene expression of&#xD;
      leukocytes, 3) subfractions of circulating leukocytes by FACS and 4) the stimulatory capacity&#xD;
      of isolated lymphocytes and monocytes in vitro. Moreover, the effects of fat or inflammation&#xD;
      on the function of the autonomic nervous system and the vasculature are studied. A second&#xD;
      focus is the impact of the interventions on signal transduction and mitochondrial function in&#xD;
      muscle and as well as on the metabolism and inflammation in subcutaneous adipose tissue in&#xD;
      muscle and fat biopsies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2009</start_date>
  <completion_date type="Actual">October 15, 2012</completion_date>
  <primary_completion_date type="Actual">September 15, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of intervention on whole body insulin sensitivity</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of intervention on systemic inflammation</measure>
    <time_frame>1-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of intervention on cellular immune mechanisms</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Adults With Normal BMI</condition>
  <arm_group>
    <arm_group_label>Fat intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous application of fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fat orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral fat load</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipopolysaccharide (LPS; US Standard Reference endotoxin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycerol intravenously</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intrevenous glycerol infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fat/Inflammation effects</intervention_name>
    <description>Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours</description>
    <arm_group_label>Fat intravenously</arm_group_label>
    <arm_group_label>Fat orally</arm_group_label>
    <arm_group_label>Glycerol intravenously</arm_group_label>
    <arm_group_label>LPS intravenously</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects&#xD;
&#xD;
          -  Age 20-40&#xD;
&#xD;
          -  BMI 20-25 mg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hyperlipidemia&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Anaemia&#xD;
&#xD;
          -  Taking drugs influencing lipid or glucose metabolism, the immune system or&#xD;
             antihypertensive medication&#xD;
&#xD;
          -  Malignancies&#xD;
&#xD;
          -  Any chronic disease&#xD;
&#xD;
          -  Autoimmune or immune compromising diseases including HIV/AIDS&#xD;
&#xD;
          -  Allergies against study drugs&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  Gall bladder diseases&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Psychiatric diseases or addiction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bettina Nowotny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Julia Szendrödi, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Healthy adults</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

